M. Tschaika

发表

Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.

P. Sharma, P. Ott, J. Rosenberg, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

J. Wolchok, S. Aamdal, A. Testori, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

P. Sharma, P. Ott, J. Rosenberg, 2016 .

Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

J. Bruix, A. Santoro, A. El-Khoueiry, 2020 .

LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

M. Kudo, T. Yau, R. Finn, 2020 .

CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).

M. Kudo, R. Finn, B. Sangro, 2020 .

CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.

M. Kudo, F. di Costanzo, A. Santoro, 2021, Journal of hepatology.

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

J. Bruix, A. El-Khoueiry, B. Sangro, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

M. Kudo, J. Furuse, G. Abou-Alfa, 2021, The Lancet. Oncology.

Sodium valproate stimulates potassium and chloride urinary excretion in rats: gender differences

J. Didziapetriene, M. Tschaika, D. Stakišaitis, 2007, BMC pharmacology.

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

P. Ascierto, P. Sharma, F. D. De Braud, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Possible association between cell membrane band 3 impairment function and renal tubular acidosis (liver diseases, malignancies and adverse drug reactions).

J. Didziapetriene, M. Tschaika, R. Mačiulaitis, 2004, Medicina.

Influence of Sodium Valproate on Sodium and Chloride Urinary Excretion in Rats, Gender Differences

M. Tschaika, D. Stakišaitis, Jurgita Grikiniene, 2005, Pharmacology.

Acute influence of sodium valproate on sodium and chloride urinary excretion in rats

M. Tschaika, D. Stakišaitis, Jurgita Grikiniene, 2005 .

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial

P. Sharma, F. D. De Braud, P. Ott, 2016, The Lancet. Oncology.

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).

P. Ascierto, P. Sharma, P. Ott, 2016 .

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

J. Furuse, G. Abou-Alfa, R. Finn, 2020, Journal of hepatology.

Effects of sodium valproate on magnesium urinary excretion in rats

M. Tschaika, D. Balsytė, 2007 .

Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040

M. Kudo, A. Santoro, B. Sangro, 2020, Journal of Hepatology.

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.

M. Kudo, A. Santoro, A. El-Khoueiry, 2020 .

IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma.

J. Trojan, M. Schroff, B. Wittig, 2012, Journal of Clinical Oncology.

Preliminary results of an ongoing phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line induction therapy (IMPACT Study).

W. Scheithauer, F. Mayer, M. Schroff, 2011, Journal of Clinical Oncology.

Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).

D. Jäger, P. Ascierto, P. Ott, 2016 .

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study

M. Tschaika, J. Koh, Yun Shen, 2020, The oncologist.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032

D. Jäger, P. Ascierto, P. Sharma, 2017 .

Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.

P. Ascierto, P. Sharma, P. Ott, 2017 .

Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study.

P. Ascierto, P. Sharma, P. Ott, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial

D. Jäger, P. Ascierto, P. Sharma, 2017 .

Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

P. Ascierto, M. Burotto, T. Ciuleanu, 2022, Cancer Research.

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

M. Kudo, A. El-Khoueiry, B. Sangro, 2023, Clinical and translational science.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

R. Govindan, K. O'Byrne, P. Postmus, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.